Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.
High triacylglycerol (TAG) levels may predict vascular risk. The effect of a statin-induced reduction in TAG levels, irrespective of HDL-C increase, on clinical outcome has not yet been addressed by an endpoint study in patients with coronary heart disease (CHD). The GREACE study compared usual with structured care aimed at achieving LDL-C = 100 mg/dL (2.6 mmol/L) by dose titration with atorvastatin. All patients had CHD and were followed for 3 years. This post hoc analysis of GREACE examines the effect of statins on TAG levels and their relation with cardiovascular disease (CVD) events in all patients and in the subgroup of patients with metabolic syndrome (MetS). Baseline TAG levels >150 mg/dL (1.7 mmol/L) were predictive of subsequent CVD events [cardiac mortality, non-fatal myocardial infarction (MI), unstable angina (UA), revascularisation, congestive heart failure (CHF), and stroke] only in statin untreated patients. Stepwise regression analysis showed that with every 20% statin-related TAG reduction there was a decrease in CVD risk by 12% (HR 0.88, 95% CI 0.75-0.95, P = 0.007) in the structured care group vs. the usual care group, by 8% (HR 0.92, 95% CI 0.81-0.97, P = 0.02) in all statin treated patients vs. the untreated ones and by 15% (HR 0.85, 95% CI 0.65-0.94, P = 0.005) in those with MetS treated with a statin vs. those untreated. Using the same analysis but only taking into consideration vascular events (cardiac mortality, non-fatal MI, UA, revascularisation, and stroke) there was a 18% (HR = 0.82, 95% CI 0.57-0.96, P = 0.03) decrease in risk in the MetS (+) patients treated with a statin vs. those not on a statin, and a decrease in risk by 16% (HR = 0.84, 95% CI 0.53-1.07, P = 0.08), when only hard vascular endpoints (cardiac mortality, non-fatal MI, and stroke) were considered. TAG levels are predictive of subsequent CVD events in statin untreated CHD patients. Statin (mainly atorvastatin)-induced decrease in TAG levels was related to a significant reduction in subsequent CVD events. This benefit was more pronounced in CHD MetS (+) patients.
Athyros
Vasilios G
VG
Atherosclerosis and Metabolic Syndrome Units, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece.
Kakafika
Anna I
AI
Papageorgiou
Athanasios A
AA
Tziomalos
Konstantinos
K
Skaperdas
Athanasios
A
Pagourelias
Efstathios
E
Pirpasopoulou
Athina
A
Karagiannis
Asterios
A
Mikhailidis
Dimitri P
DP
D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy*; D005215:Fasting; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D012044:Regression Analysis; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood*
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D011758:Pyrroles; D014280:Triglycerides; D000069059:Atorvastatin
Am J Kidney Dis. 2006 Mar;47(3):561; author reply 562
16490637
J Am Coll Cardiol. 2005 Apr 5;45(7):1003-12
15808755
Circulation. 2004 Jan 6;109(1):42-6
14676144
Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):2026-31
11742880
J Cardiovasc Risk. 1996 Apr;3(2):213-9
8836866
Am J Cardiol. 2004 Jan 15;93(2):136-41
14715336
Am J Kidney Dis. 2004 Apr;43(4):589-99
15042535
Circulation. 2006 May 16;113(19):2363-72
16702489
Int J Cardiol. 2006 Mar 22;108(1):89-95
16085325
Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):189-97
10634817
Expert Opin Biol Ther. 2007 Jan;7(1):53-72
17150019
Curr Med Res Opin. 2002;18(4):220-8
12201623
Coron Artery Dis. 1996 Nov;7(11):843-50
8993943
Am J Cardiol. 2002 Oct 1;90(7):689-96
12356379
Circulation. 2001 Dec 18;104(25):3046-51
11748098
J Clin Pathol. 2004 Jul;57(7):728-34
15220366
Atherosclerosis. 2003 Jun;168(2):397-8
12801625
Am J Cardiol. 1992 Dec 14;70(19):10H-13H
1466311
Diabetes Care. 2002 Jul;25(7):1198-202
12087019
JAMA. 2001 May 16;285(19):2486-97
11368702
N Engl J Med. 1999 Aug 5;341(6):410-8
10438259
Diabetes Care. 2004 Jul;27(7):1735-40
15220255
Curr Med Res Opin. 2006 Mar;22(3):511-28
16574035
Am J Cardiol. 2002 Jul 15;90(2):139-43
12106843
Curr Med Chem. 2005;12(17):1931-45
16101498
N Engl J Med. 1993 Apr 29;328(17):1220-5
8464432
Platelets. 2005 Mar;16(2):65-71
15823861
Circulation. 2005 Oct 25;112(17):2735-52
16157765
Circulation. 2004 Jul 13;110(2):227-39
15249516
J Am Coll Cardiol. 2007 Jan 30;49(4):403-14
17258085
Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1718-22
15947240
Curr Drug Targets. 2007 Mar;8(3):483-8
17348840
Curr Med Res Opin. 2004;20(2):241-7
15006019
Am J Cardiol. 2004 Jan 1;93(1):31-9
14697462
Am J Cardiol. 1998 Feb 26;81(4A):66B-69B
9526817
Curr Med Res Opin. 2004 Sep;20(9):1385-92
15383187
Circulation. 1992 Jan;85(1):37-45
1728471
Metabolism. 2002 Mar;51(3):334-42
11887170
Heart. 2005 Dec;91 Suppl 5:v1-52
16365341
Curr Med Res Opin. 2003;19(6):540-56
14594527
Am Heart J. 1986 Aug;112(2):432-7
3739899
Lancet. 2005 Nov 26;366(9500):1849-61
16310551
J Hum Hypertens. 2004 Nov;18(11):781-8
15229622